Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OSI Bullish On Increased Tarceva Sales

This article was originally published in The Pink Sheet Daily

Executive Summary

Oncologic is “entrenched” in the market, not greatly vulnerable to competition from Erbitux, CEO Goddard tells investors.

You may also be interested in...



Through Alimta Lens, OSI Views Positive Near-term Advantages For Tarceva In Lung Cancer

Approval of Lilly’s Alimta in first-line NSCLC and recent data showing it is ineffective in squamous histologies could give Tarceva a leg up in second-line setting.

Through Alimta Lens, OSI Views Positive Near-term Advantages For Tarceva In Lung Cancer

Approval of Lilly’s Alimta in first-line NSCLC and recent data showing it is ineffective in squamous histologies could give Tarceva a leg up in second-line setting.

AstraZeneca’s Recentin Will Move Into Phase III For Colorectal Cancer, But Not NSCLC

Firm will study VEGF inhibitor plus chemotherapy versus Genentech’s Avastin in first-line colorectal cancer.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel